189 related articles for article (PubMed ID: 18763281)
1. Mechanism and pathobiologic implications of CHFR promoter methylation in gastric carcinoma.
Gao YJ; Xin Y; Zhang JJ; Zhou J
World J Gastroenterol; 2008 Aug; 14(32):5000-7. PubMed ID: 18763281
[TBL] [Abstract][Full Text] [Related]
2. Pathobiologic implications of methylation and expression status of Runx3 and CHFR genes in gastric cancer.
Hu SL; Huang DB; Sun YB; Wu L; Xu WP; Yin S; Chen J; Jiang XD; Shen G
Med Oncol; 2011 Jun; 28(2):447-54. PubMed ID: 20300977
[TBL] [Abstract][Full Text] [Related]
3. Promoter methylation of p16, Runx3, DAPK and CHFR genes is frequent in gastric carcinoma.
Hu SL; Kong XY; Cheng ZD; Sun YB; Shen G; Xu WP; Wu L; Xu XC; Jiang XD; Huang DB
Tumori; 2010; 96(5):726-33. PubMed ID: 21302620
[TBL] [Abstract][Full Text] [Related]
4. Aberrant promoter hypermethylation of the CHFR gene in oral squamous cell carcinomas.
Baba S; Hara A; Kato K; Long NK; Hatano Y; Kimura M; Okano Y; Yamada Y; Shibata T
Oncol Rep; 2009 Nov; 22(5):1173-9. PubMed ID: 19787237
[TBL] [Abstract][Full Text] [Related]
5. Promoter methylation of CHFR gene in gastric carcinoma tissues detected using two methods.
Cheng ZD; Hu SL; Sun YB; Xu WP; Shen G; Kong XY
Chin J Cancer; 2010 Feb; 29(2):163-6. PubMed ID: 20109344
[TBL] [Abstract][Full Text] [Related]
6. Predictive value of CHFR and MLH1 methylation in human gastric cancer.
Li Y; Yang Y; Lu Y; Herman JG; Brock MV; Zhao P; Guo M
Gastric Cancer; 2015 Apr; 18(2):280-7. PubMed ID: 24748501
[TBL] [Abstract][Full Text] [Related]
7. Epigenetic and genetic silencing of CHFR in esophageal adenocarcinomas.
Soutto M; Peng D; Razvi M; Ruemmele P; Hartmann A; Roessner A; Schneider-Stock R; El-Rifai W
Cancer; 2010 Sep; 116(17):4033-42. PubMed ID: 20564104
[TBL] [Abstract][Full Text] [Related]
8. Promoter hypermethylation of the Chfr gene in neoplastic and non-neoplastic gastric epithelia.
Honda T; Tamura G; Waki T; Kawata S; Nishizuka S; Motoyama T
Br J Cancer; 2004 May; 90(10):2013-6. PubMed ID: 15138487
[TBL] [Abstract][Full Text] [Related]
9. Aberrant methylation of the CHFR gene in digestive tract cancer.
Morioka Y; Hibi K; Sakai M; Koike M; Fujiwara M; Kodera Y; Ito K; Nakao A
Anticancer Res; 2006; 26(3A):1791-5. PubMed ID: 16827108
[TBL] [Abstract][Full Text] [Related]
10. Checkpoint with forkhead-associated and ring finger promoter hypermethylation correlates with microsatellite instability in gastric cancer.
Oki E; Zhao Y; Yoshida R; Masuda T; Ando K; Sugiyama M; Tokunaga E; Morita M; Kakeji Y; Maehara Y
World J Gastroenterol; 2009 May; 15(20):2520-5. PubMed ID: 19469003
[TBL] [Abstract][Full Text] [Related]
11. Promoter hypermethylation and silencing of CHFR mitotic stress checkpoint gene in human gastric cancers.
Kang HC; Kim IJ; Park JH; Shin Y; Park HW; Ku JL; Yang HK; Lee KU; Choe KJ; Park JG
Oncol Rep; 2004 Jul; 12(1):129-33. PubMed ID: 15201973
[TBL] [Abstract][Full Text] [Related]
12. Alternative efficacy-predicting markers for paclitaxel instead of CHFR in non-small-cell lung cancer.
Takeshita M; Koga T; Takayama K; Yano T; Maehara Y; Nakanishi Y; Sueishi K
Cancer Biol Ther; 2010 Nov; 10(9):933-41. PubMed ID: 20855974
[TBL] [Abstract][Full Text] [Related]
13. Methylation-independent CHFR expression is a potential biomarker affecting prognosis in acute myeloid leukemia.
Zhou JD; Zhang TJ; Li XX; Ma JC; Guo H; Wen XM; Yao DM; Zhang W; Lin J; Qian J
J Cell Physiol; 2018 Jun; 233(6):4707-4714. PubMed ID: 29115660
[TBL] [Abstract][Full Text] [Related]
14. Aberrant gene methylation in the lymph nodes provides a possible marker for diagnosing micrometastasis in gastric cancer.
Hiraki M; Kitajima Y; Sato S; Mitsuno M; Koga Y; Nakamura J; Hashiguchi K; Noshiro H; Miyazaki K
Ann Surg Oncol; 2010 Apr; 17(4):1177-86. PubMed ID: 19957042
[TBL] [Abstract][Full Text] [Related]
15. CHFR promoter hypermethylation and reduced CHFR mRNA expression in ovarian cancer.
Gao Y; Lou G; Zhang GM; Sun XW; Ma YY; Yang YM; Liu G
Int J Biol Markers; 2009; 24(2):83-9. PubMed ID: 19634111
[TBL] [Abstract][Full Text] [Related]
16. Aberrant gene methylation in the peritoneal fluid is a risk factor predicting peritoneal recurrence in gastric cancer.
Hiraki M; Kitajima Y; Sato S; Nakamura J; Hashiguchi K; Noshiro H; Miyazaki K
World J Gastroenterol; 2010 Jan; 16(3):330-8. PubMed ID: 20082478
[TBL] [Abstract][Full Text] [Related]
17. [Aberrant promoter hypermethylation of CHFR in nasopharyngeal carcinoma].
Huang T; Du C; Yu N; Xiao X; Zhou X; Wang S; Huang G; Zhang Z
Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2011 Aug; 25(16):746-50. PubMed ID: 22070084
[TBL] [Abstract][Full Text] [Related]
18. DNA methylation of CHFR is not a predictor of the response to docetaxel and paclitaxel in advanced and recurrent gastric cancer.
Yoshida K; Hamai Y; Suzuki T; Sanada Y; Oue N; Yasui W
Anticancer Res; 2006; 26(1A):49-54. PubMed ID: 16475678
[TBL] [Abstract][Full Text] [Related]
19. Association of CHFR Promoter Methylation with Treatment Outcomes of Irinotecan-Based Chemotherapy in Metastatic Colorectal Cancer.
Cha Y; Kim SY; Yeo HY; Baek JY; Choi MK; Jung KH; Dong SM; Chang HJ
Neoplasia; 2019 Jan; 21(1):146-155. PubMed ID: 30562637
[TBL] [Abstract][Full Text] [Related]
20. Methylation of gene CHFR promoter in acute leukemia cells.
Gong H; Liu W; Zhou J; Xu H
J Huazhong Univ Sci Technolog Med Sci; 2005; 25(3):240-2. PubMed ID: 16201259
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
